Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman(Rutgers, The State University of New Jersey), Jeffery S. Russell(Moffitt Cancer Center), Omid Hamid(Angeles Clinic and Research Institute), Shailender Bhatia(University of Washington Medical Center), Patrick Terheyden(University of Lübeck), Sandra P. D’Angelo(Cornell University), Kent C. Shih(Tennessee Oncology), Célèste Lebbé(Inserm), Gerald P. Linette(Washington University in St. Louis), Michèle Milella, Isaac Brownell(National Cancer Institute), Karl D. Lewis(University of Colorado Denver), Jochen H. Lorch(Dana-Farber Cancer Institute), Kevin M. Chin(Ono Pharmaceutical (United States)), Lisa Mahnke(Ono Pharmaceutical (United States)), Anja von Heydebreck(Merck (Germany)), Jean-Marie Cuillerot(Ono Pharmaceutical (United States)), Paul Nghiem(University of Washington Medical Center)
The Lancet Oncology
September 7, 2016
Cited by 1,213Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis